National Cancer Registry and Analysis Service (NCRAS), England, UK.
Policy and Information, Cancer Research UK, England, UK.
Cancer Epidemiol. 2019 Feb;58:184-192. doi: 10.1016/j.canep.2018.10.019. Epub 2019 Jan 9.
International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions.
Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden.
Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment.
Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap' between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.
国际癌症生存比较利用癌症登记数据报告癌症生存情况,为癌症政策和实践的制定提供信息。像国际癌症基准合作组织(ICBP)这样的研究有责任在得出结论之前了解登记差异对生存的影响。
关键信息提供者报告了在捕获发病日期、死亡证明处理和多原发肿瘤登记方面的登记实践差异。敏感性分析使用英格兰和瑞典的基线和补充癌症登记数据估计了这些差异对一年生存率的影响。
根据肿瘤部位和管辖区的不同,登记实践的差异导致未经调整(来自之前 ICBP 生存数据的估计)和调整(考虑登记差异后重新计算的估计)的一年生存率差异高达 7.3 个百分点。四个管辖区的一年生存率估计受到调整的影响:新南威尔士州、挪威、安大略省、瑞典。调整后,瑞典和安大略省的生存率降低,但它们仍然是乳腺癌和卵巢癌生存率最高的管辖区。未经调整的瑞典肺癌生存率最高,为 43.6%,调整后为 39.0%,使维多利亚州和马尼托巴省的生存率最高,为 42.7%。对于结直肠癌,维多利亚州最高的 85.1%的生存率在调整后保持不变。
基于人群的癌症生存比较可能受到登记偏差的影响,这些偏差可能会影响报告的人群之间的“生存差距”。应努力在国际上应用一致的登记做法。同时,生存比较研究应承认或调整可能影响其结论的登记偏差。